<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608491</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00018064</org_study_id>
    <secondary_id>U01HL084904-04</secondary_id>
    <secondary_id>U01HL084904</secondary_id>
    <secondary_id>522</secondary_id>
    <nct_id>NCT00608491</nct_id>
  </id_info>
  <brief_title>Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)</brief_title>
  <acronym>CARRESS</acronym>
  <official_title>CARdiorenal REScue Study in Acute Decompensated Heart Failure: CARRESS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHF Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is a serious condition in which the heart's ability to pump blood through the
      body is impaired, often making a person feel weak or fatigued. When a person's condition
      worsens to the point of hospitalization, that person is said to have acute decompensated
      heart failure (ADHF). Abnormal kidney function in association with cardiac distress, known as
      cardiorenal syndrome, is a common complication of heart failure and causes further medical
      problems and need for hospitalization. While there are various effective treatments for heart
      failure, more research is needed to determine the best treatment for targeting both ADHF and
      cardiorenal syndrome. This study will compare the safety and effectiveness of ultrafiltration
      versus standard medical drug therapy in improving renal function and relieving fluid buildup
      in people hospitalized with ADHF and cardiorenal syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a common condition that affects approximately 5 million people in the United
      States, with 550,000 new cases diagnosed each year. Common symptoms of heart failure include
      swelling and fluid buildup in the legs, feet, and/or lungs; shortness of breath; coughing;
      elevated heart rate; change in appetite; and fatigue. If left untreated, the condition of the
      heart may deteriorate so far that the person undergoes ADHF. The number of hospitalizations
      attributed to ADHF has risen significantly, with many people readmitted soon after discharge
      because of recurring symptoms or further medical complications, such as cardiorenal syndrome.
      Current heart failure treatments focus on removing excess fluid buildup, often by increasing
      urination with diuretic medications or by draining directly from the veins. Direct drainage
      from the veins, also known as ultrafiltration, may be the more effective method for treating
      people with ADHF and cardiorenal syndrome. This study will compare the safety and
      effectiveness of ultrafiltration versus standard medical drug therapy in improving renal
      function and relieving fluid buildup in people hospitalized with ADHF and cardiorenal
      syndrome.

      Participation in this study will last 60 days. All potential participants will undergo
      initial screening, which will include a medical history, physical exam, blood draws,
      measurements of fluid intake and urine output, and questionnaires. These same evaluations and
      procedures will be repeated at various points during the hospital stay. Eligible participants
      will be randomly assigned to receive standard medical drug therapy or fluid removal by
      ultrafiltration. Standard medical drug therapy will involve the intravenous delivery of
      diuretics and possibly other doctor-recommended medications. Ultrafiltration will involve
      intravenously removing blood, passing it through an ultrafiltration device, and then
      returning the blood to the participant. During ultrafiltration, participants will be treated
      with a blood thinner through the IV, as well.

      Follow-up assessments will occur at Days 30 and 60 after treatment. Follow-up assessments
      will include measurements of fluid intake, urine output, and vital signs; blood draws;
      physical exams; and questions about medications and status of recovery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>Change from Baseline to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Change from Baseline to Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glomerular Filtration Rate</measure>
    <time_frame>Change from Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine</measure>
    <time_frame>Change from Baseline to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glomerular Filtration Rate</measure>
    <time_frame>Change from Baseline to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Weight</measure>
    <time_frame>Change from Baseline to Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Weight</measure>
    <time_frame>Change from Baseline to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Change from Baseline to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Weight</measure>
    <time_frame>Change from Baseline to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Change from Baseline to Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Net Fluid Loss</measure>
    <time_frame>Randomization through Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Net Fluid Loss</measure>
    <time_frame>Randomization through Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Net Fluid Loss</measure>
    <time_frame>Randomization through Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Net Fluid Loss</measure>
    <time_frame>Randomization through Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Net Fluid Loss</measure>
    <time_frame>Randomization through Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Net Fluid Loss</measure>
    <time_frame>Randomization through Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Net Fluid Loss</measure>
    <time_frame>Randomization through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea Visual Analog Scale</measure>
    <time_frame>Change from Baseline to Day 4</time_frame>
    <description>Scale range: -100 , +100
-100=worse, +100=better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Visual Analog Scale</measure>
    <time_frame>Change from Baseline to Day 4</time_frame>
    <description>Scale range: -100 , +100
-100=worse, +100=better Participants asked to mark their global well being on a 10 cm vertical line, with the top labeled &quot;best you have ever felt&quot; and the bottom labeled &quot;worst you have ever felt&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dyspnea Visual Analog Scale</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
    <description>Scale range: -100 , +100
-100=worse, +100=better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Visual Analog Scale</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
    <description>Scale range: -100 , +100
-100=worse, +100=better Participants asked to mark their global well being on a 10 cm vertical line, with the top labeled &quot;best you have ever felt&quot; and the bottom labeled &quot;worst you have ever felt&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Furosemide-Equivalent Dose</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
    <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Sodium Level</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Potassium Level</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Urea Nitrogen/Urea</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Bicarbonate Level</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Hemoglobin Level</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Sodium Level</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Potassium Level</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Urea Nitrogen/Urea</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Bicarbonate Level</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Hemoglobin Level</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Cystatin C</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Uric Acid</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood N- Terminal Pro- BNP</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Renin Activity</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood High Sensitivity Troponin I</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Aldosterone</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Procollagen III N-terminal Propepide</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Endothelin-1</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood High Sensitivity C-Reactive Protein</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</measure>
    <time_frame>Baseline to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Cystatin C</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Uric Acid</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood N Terminal Pro-Natriuretic Peptide</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Renin Activity</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood High Sensitivity Troponin I</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Aldosterone</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Procollagen III N-terminal Propepide</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Endothelin-1</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood High Sensitivity C-Reactive Protein</measure>
    <time_frame>Baseline to Day 7/Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Change</measure>
    <time_frame>Baseline to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Furosemide-Equivalent Dose</measure>
    <time_frame>Baseline to Day 30</time_frame>
    <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Change</measure>
    <time_frame>Baseline to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate Change</measure>
    <time_frame>Baseline to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Change</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Furosemide-Equivalent Dose</measure>
    <time_frame>Baseline to Day 60</time_frame>
    <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Available Serum Creatinine Change</measure>
    <time_frame>Baseline to Day 60</time_frame>
    <description>Core laboratory when available. If not available, local laboratory results were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Available Glomerular Filtration Rate Change</measure>
    <time_frame>Baseline to Day 60</time_frame>
    <description>Core laboratory when available. If not available, local laboratory results were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Uric Acid</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Cystatin C</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood N Terminal Pro - B Natriuretic Peptides</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Renin Activity</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood High Sensitivity Troponin I</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Aldosterone</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Procollagen III N-terminal Propepide</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Endothelin-1</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood High Sensitivity C-Reactive Protein</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Stepped pharmacologic care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrafiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stepped pharmacologic care</intervention_name>
    <description>Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.</description>
    <arm_group_label>Stepped pharmacologic care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrafiltration</intervention_name>
    <description>All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.</description>
    <arm_group_label>Ultrafiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  age 18 or older

          -  admitted to the hospital with a primary diagnosis of decompensated heart failure

          -  onset of cardiorenal syndrome after hospitalization or pre-hospitalization

          -  after hospitalization - onset of cardiorenal syndrome after hospitalization must occur
             within 10 days from the time of admission after receiving IV diuretics

          -  pre-hospitalization - onset of cardiorenal syndrome pre-hospitalization must occur
             within 12 weeks of the index hospitalization in the setting of escalating doses of
             outpatient diuretics

          -  persistent volume overload

        Exclusion criteria:

          -  intravascular volume depletion based on investigatorâ€Ÿs clinical assessment

          -  acute coronary syndrome within 4 weeks

          -  indication for hemodialysis

          -  creatinine &gt; 3.5 mg per deciliter at admission to the hospital

          -  systolic blood pressure &lt; 90 mmHg at the time of enrollment

          -  alternative explanation for worsening renal function such as obstructive
             nephropathy,contrast induced nephropathy, acute tubular necrosis

          -  Hematocrit &gt; 45%

          -  poor venous access

          -  clinical instability likely to require the addition of intravenous vasoactive drugs
             including vasodilators and/or inotropic agents

          -  allergy or contraindications to the use of heparin

          -  the use of iodinated radio contrast material in the last 72 hours or anticipated use
             of IV contrast during the current hospitalization

          -  known bilateral renal artery stenosis

          -  active myocarditis

          -  hypertrophic obstructive cardiomyopathy

          -  severe valvular stenosis

          -  complex congenital heart disease

          -  sepsis or ongoing systemic infection

          -  enrollment in another clinical trial involving medical or device based interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry L. Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morehouse School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Heart Failure Network</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont - Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T - 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012 Dec 13;367(24):2296-304. doi: 10.1056/NEJMoa1210357. Epub 2012 Nov 6.</citation>
    <PMID>23131078</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>February 18, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2013</results_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Decompensated Heart Failure</keyword>
  <keyword>Acute Decompensated Heart Failure With Cardiorenal Syndrome</keyword>
  <keyword>Cardiorenal Syndrome</keyword>
  <keyword>Persistent Congestion</keyword>
  <keyword>Ultra Filtration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Vasodilator Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stepped Pharmacologic Care</title>
          <description>Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes</description>
        </group>
        <group group_id="P2">
          <title>Ultrafiltration</title>
          <description>Participants will receive ultrafiltration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stepped Pharmacologic Care</title>
          <description>Participants will receive stepped pharmacologic care</description>
        </group>
        <group group_id="B2">
          <title>Ultrafiltration</title>
          <description>Participants will receive ultrafiltration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="13.7"/>
                    <measurement group_id="B2" value="68.9" spread="12.0"/>
                    <measurement group_id="B3" value="68.0" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>Change from Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.53"/>
                    <measurement group_id="O2" value="0.23" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glomerular Filtration Rate</title>
        <time_frame>Change from Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glomerular Filtration Rate</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="10.94"/>
                    <measurement group_id="O2" value="0.93" spread="14.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine</title>
        <time_frame>Change from Baseline to Day 7</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.60"/>
                    <measurement group_id="O2" value="0.11" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glomerular Filtration Rate</title>
        <time_frame>Change from Baseline to Day 7</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glomerular Filtration Rate</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="9.32"/>
                    <measurement group_id="O2" value="1.82" spread="13.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Weight</title>
        <time_frame>Change from Baseline to Day 1</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Weight</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="5.2"/>
                    <measurement group_id="O2" value="-4.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Weight</title>
        <time_frame>Change from Baseline to Day 2</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Weight</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="8.6"/>
                    <measurement group_id="O2" value="-8.8" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <time_frame>Change from Baseline to Day 3</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="10.5"/>
                    <measurement group_id="O2" value="-11.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Weight</title>
        <time_frame>Change from Baseline to Day 5</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Weight</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" spread="12.0"/>
                    <measurement group_id="O2" value="-14.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <time_frame>Change from Baseline to Day 6</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" spread="15.3"/>
                    <measurement group_id="O2" value="-15.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Net Fluid Loss</title>
        <time_frame>Randomization through Day 1</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Net Fluid Loss</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1714.1" spread="1400.2"/>
                    <measurement group_id="O2" value="2193.6" spread="1554.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Net Fluid Loss</title>
        <time_frame>Randomization through Day 2</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Net Fluid Loss</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3814.2" spread="2384.2"/>
                    <measurement group_id="O2" value="4705.8" spread="2626.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Weight</title>
        <time_frame>Change from Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="11.3"/>
                    <measurement group_id="O2" value="-12.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Net Fluid Loss</title>
        <time_frame>Randomization through Day 3</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Net Fluid Loss</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5706.8" spread="3490.6"/>
                    <measurement group_id="O2" value="6257.1" spread="3519.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Net Fluid Loss</title>
        <time_frame>Randomization through Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Net Fluid Loss</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7081.5" spread="4183.4"/>
                    <measurement group_id="O2" value="7443.0" spread="4328.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Net Fluid Loss</title>
        <time_frame>Randomization through Day 5</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Net Fluid Loss</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8358.8" spread="5034.5"/>
                    <measurement group_id="O2" value="8308.4" spread="5178.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Net Fluid Loss</title>
        <time_frame>Randomization through Day 6</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Net Fluid Loss</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9700.7" spread="6945.9"/>
                    <measurement group_id="O2" value="9822.1" spread="6001.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Net Fluid Loss</title>
        <time_frame>Randomization through Day 7</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Net Fluid Loss</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11659.6" spread="9142.0"/>
                    <measurement group_id="O2" value="10595.1" spread="7097.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea Visual Analog Scale</title>
        <description>Scale range: -100 , +100
-100=worse, +100=better</description>
        <time_frame>Change from Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea Visual Analog Scale</title>
          <description>Scale range: -100 , +100
-100=worse, +100=better</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="27.8"/>
                    <measurement group_id="O2" value="16.5" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global Visual Analog Scale</title>
        <description>Scale range: -100 , +100
-100=worse, +100=better Participants asked to mark their global well being on a 10 cm vertical line, with the top labeled â€œbest you have ever feltâ€ and the bottom labeled â€œworst you have ever feltâ€.</description>
        <time_frame>Change from Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Visual Analog Scale</title>
          <description>Scale range: -100 , +100
-100=worse, +100=better Participants asked to mark their global well being on a 10 cm vertical line, with the top labeled â€œbest you have ever feltâ€ and the bottom labeled â€œworst you have ever feltâ€.</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="25.8"/>
                    <measurement group_id="O2" value="13.7" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dyspnea Visual Analog Scale</title>
        <description>Scale range: -100 , +100
-100=worse, +100=better</description>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dyspnea Visual Analog Scale</title>
          <description>Scale range: -100 , +100
-100=worse, +100=better</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="27.6"/>
                    <measurement group_id="O2" value="19.4" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global Visual Analog Scale</title>
        <description>Scale range: -100 , +100
-100=worse, +100=better Participants asked to mark their global well being on a 10 cm vertical line, with the top labeled â€œbest you have ever feltâ€ and the bottom labeled â€œworst you have ever feltâ€.</description>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Visual Analog Scale</title>
          <description>Scale range: -100 , +100
-100=worse, +100=better Participants asked to mark their global well being on a 10 cm vertical line, with the top labeled â€œbest you have ever feltâ€ and the bottom labeled â€œworst you have ever feltâ€.</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="30.2"/>
                    <measurement group_id="O2" value="16.9" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Furosemide-Equivalent Dose</title>
        <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Furosemide-Equivalent Dose</title>
          <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="166.5"/>
                    <measurement group_id="O2" value="-20.6" spread="116.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Sodium Level</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Sodium Level</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="3.60"/>
                    <measurement group_id="O2" value="-2.3" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Potassium Level</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Potassium Level</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.63"/>
                    <measurement group_id="O2" value="0.26" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Urea Nitrogen/Urea</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Urea Nitrogen/Urea</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="18.29"/>
                    <measurement group_id="O2" value="12.54" spread="24.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Bicarbonate Level</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Bicarbonate Level</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="3.82"/>
                    <measurement group_id="O2" value="-1.01" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Hemoglobin Level</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Hemoglobin Level</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.76"/>
                    <measurement group_id="O2" value="-0.01" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Sodium Level</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Sodium Level</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="3.70"/>
                    <measurement group_id="O2" value="-2.02" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Potassium Level</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Potassium Level</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.60"/>
                    <measurement group_id="O2" value="0.27" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Urea Nitrogen/Urea</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Urea Nitrogen/Urea</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="20.69"/>
                    <measurement group_id="O2" value="13.81" spread="23.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Bicarbonate Level</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Bicarbonate Level</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" spread="4.50"/>
                    <measurement group_id="O2" value="-0.70" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Hemoglobin Level</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Hemoglobin Level</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.94"/>
                    <measurement group_id="O2" value="-0.02" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Cystatin C</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Cystatin C</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.52"/>
                    <measurement group_id="O2" value="0.22" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Uric Acid</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Uric Acid</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.44"/>
                    <measurement group_id="O2" value="-0.23" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood N- Terminal Pro- BNP</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood N- Terminal Pro- BNP</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-978.61" spread="2902.06"/>
                    <measurement group_id="O2" value="-814.45" spread="9238.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Renin Activity</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Renin Activity</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ng/mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="45.65"/>
                    <measurement group_id="O2" value="12.67" spread="31.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood High Sensitivity Troponin I</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood High Sensitivity Troponin I</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.38" spread="369.85"/>
                    <measurement group_id="O2" value="-38.95" spread="1027.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Aldosterone</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Aldosterone</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-109.13" spread="489.50"/>
                    <measurement group_id="O2" value="-3.07" spread="485.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Procollagen III N-terminal Propepide</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Procollagen III N-terminal Propepide</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="4.69"/>
                    <measurement group_id="O2" value="-0.64" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Endothelin-1</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Endothelin-1</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="1.70"/>
                    <measurement group_id="O2" value="-1.13" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood High Sensitivity C-Reactive Protein</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood High Sensitivity C-Reactive Protein</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="46.14"/>
                    <measurement group_id="O2" value="1.89" spread="28.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</title>
        <time_frame>Baseline to Day 4</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" spread="11.93"/>
                    <measurement group_id="O2" value="9.07" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Cystatin C</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Cystatin C</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.48"/>
                    <measurement group_id="O2" value="0.09" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Uric Acid</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Uric Acid</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.85"/>
                    <measurement group_id="O2" value="-0.15" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood N Terminal Pro-Natriuretic Peptide</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood N Terminal Pro-Natriuretic Peptide</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1071.88" spread="3309.45"/>
                    <measurement group_id="O2" value="-740.82" spread="8604.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Renin Activity</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Renin Activity</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ng/mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="40.70"/>
                    <measurement group_id="O2" value="11.40" spread="32.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood High Sensitivity Troponin I</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood High Sensitivity Troponin I</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.28" spread="350.45"/>
                    <measurement group_id="O2" value="-37.16" spread="1231.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Aldosterone</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Aldosterone</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.26" spread="507.96"/>
                    <measurement group_id="O2" value="68.13" spread="624.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Procollagen III N-terminal Propepide</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Procollagen III N-terminal Propepide</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="5.90"/>
                    <measurement group_id="O2" value="-0.93" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Endothelin-1</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Endothelin-1</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="1.85"/>
                    <measurement group_id="O2" value="-1.24" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.21" spread="15.79"/>
                    <measurement group_id="O2" value="10.54" spread="15.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood High Sensitivity C-Reactive Protein</title>
        <time_frame>Baseline to Day 7/Discharge</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood High Sensitivity C-Reactive Protein</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.39" spread="48.56"/>
                    <measurement group_id="O2" value="2.18" spread="37.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Change</title>
        <time_frame>Baseline to Day 30</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Change</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="22.4"/>
                    <measurement group_id="O2" value="-13.4" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Furosemide-Equivalent Dose</title>
        <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
        <time_frame>Baseline to Day 30</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Furosemide-Equivalent Dose</title>
          <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="188.3"/>
                    <measurement group_id="O2" value="27.3" spread="120.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Change</title>
        <time_frame>Baseline to Day 30</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Change</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.68"/>
                    <measurement group_id="O2" value="-0.12" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate Change</title>
        <time_frame>Baseline to Day 30</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate Change</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.95" spread="11.85"/>
                    <measurement group_id="O2" value="6.07" spread="16.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Change</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Change</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" spread="21.1"/>
                    <measurement group_id="O2" value="-15.4" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Furosemide-Equivalent Dose</title>
        <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Furosemide-Equivalent Dose</title>
          <description>Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40)</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="122.5"/>
                    <measurement group_id="O2" value="8.8" spread="128.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Available Serum Creatinine Change</title>
        <description>Core laboratory when available. If not available, local laboratory results were used.</description>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Best Available Serum Creatinine Change</title>
          <description>Core laboratory when available. If not available, local laboratory results were used.</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.61"/>
                    <measurement group_id="O2" value="-0.12" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Available Glomerular Filtration Rate Change</title>
        <description>Core laboratory when available. If not available, local laboratory results were used.</description>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Best Available Glomerular Filtration Rate Change</title>
          <description>Core laboratory when available. If not available, local laboratory results were used.</description>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.86" spread="13.26"/>
                    <measurement group_id="O2" value="5.63" spread="16.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Uric Acid</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Uric Acid</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="2.28"/>
                    <measurement group_id="O2" value="-0.54" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Cystatin C</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Cystatin C</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.48"/>
                    <measurement group_id="O2" value="-0.03" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood N Terminal Pro - B Natriuretic Peptides</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood N Terminal Pro - B Natriuretic Peptides</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-490.56" spread="5638.86"/>
                    <measurement group_id="O2" value="-937.69" spread="7389.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Renin Activity</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Renin Activity</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ng/mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="41.12"/>
                    <measurement group_id="O2" value="0.54" spread="20.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood High Sensitivity Troponin I</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood High Sensitivity Troponin I</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.48" spread="106.70"/>
                    <measurement group_id="O2" value="-73.58" spread="511.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Aldosterone</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Aldosterone</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.91" spread="672.21"/>
                    <measurement group_id="O2" value="40.35" spread="471.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Procollagen III N-terminal Propepide</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Procollagen III N-terminal Propepide</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="5.25"/>
                    <measurement group_id="O2" value="0.58" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Endothelin-1</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Endothelin-1</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="1.58"/>
                    <measurement group_id="O2" value="-1.32" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood High Sensitivity C-Reactive Protein</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood High Sensitivity C-Reactive Protein</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.62" spread="59.58"/>
                    <measurement group_id="O2" value="1.99" spread="44.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</title>
        <time_frame>Baseline to Day 60</time_frame>
        <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Stepped Pharmacologic Care</title>
            <description>Participants will receive stepped pharmacologic care</description>
          </group>
          <group group_id="O2">
            <title>Ultrafiltration</title>
            <description>Participants will receive ultrafiltration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Carboxy-terminal Telopeptide of Collagen Type I</title>
          <population>Participants analyzed consisted of those participants who had the endpoint data available to be derived.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="13.44"/>
                    <measurement group_id="O2" value="4.57" spread="27.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stepped Pharmacologic Care</title>
          <description>Participants will receive stepped pharmacologic care</description>
        </group>
        <group group_id="E2">
          <title>Ultrafiltration</title>
          <description>Participants will receive ultrafiltration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Heparin-Induced Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pulseless Electrical Activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Urinary Tract Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jenny Ibarra</name_or_title>
      <organization>Duke University</organization>
      <phone>9192363291</phone>
      <email>jenny.ibarra@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

